Welcome to our dedicated page for Cyanotech news (Ticker: CYAN), a resource for investors and traders seeking the latest updates and insights on Cyanotech stock.
Cyanotech Corporation reports developments tied to microalgae-based nutrition and health dietary supplement products, including BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica®. The company produces microalgae at its Kona, Hawaii facility using patented and proprietary technology and sells through its Nutrex-Hawaii consumer channel, U.S. retail locations, online sales, bulk ingredient markets, and manufacturers and marketers in dietary supplement, nutraceutical and cosmeceutical categories.
Recurring news covers quarterly and annual financial results, sales trends by bulk, packaged goods and online channels, gross margin and production-efficiency commentary, inventory and supply management, contract extraction activity, and product-format launches such as astaxanthin and spirulina gummies.
Cyanotech (OTCQB: CYAN) reported results for Q2 fiscal 2026 ended September 30, 2025, showing sales and margin improvement. Net sales were $6,976,000, up 19.3% YoY, and gross profit rose to $2,393,000 with a 34.3% gross margin versus 25.3% a year earlier. Operating income was $190,000 versus an operating loss of $975,000 in Q2 FY2025. Net income for the quarter was $1,000 (≈$0.00 per diluted share) versus a $1,150,000 loss a year prior.
For the trailing 12 months ended September 30, 2025, net sales were $25,269,000 and gross margin improved to 32.0%; trailing twelve‑month net loss narrowed to $1,776,000.
Cyanotech (OTCQB: CYAN), a leader in microalgae-based nutrition supplements, reported its Q1 fiscal 2026 results. The company posted net sales of $5.82 million, a slight decrease of 1.3% from Q1 fiscal 2025. Despite flat revenue, gross margin improved significantly to 30.5% from 25.0% year-over-year.
The company reduced its net loss to $926,000 ($0.13 per share) compared to $1.2 million ($0.17 per share) in the prior year. For the trailing twelve months, Cyanotech achieved net sales of $24.14 million with a gross profit margin of 29.7%, showing improvement from 24.7% in the previous period.
Cyanotech (OTCQB: CYAN) reported its Q3 FY2025 financial results, showing a 10.6% increase in net sales to $6,172,000 compared to $5,582,000 in Q3 FY2024. The company's gross profit margin improved to 35.3% from 29.5% year-over-year.
For Q3 FY2025, operating loss narrowed to $50,000 from $848,000 in the prior year, while net loss decreased to $224,000 ($0.03 per share) from $1,020,000 ($0.16 per share).
For the first nine months of FY2025, net sales increased 4.8% to $17,915,000, though gross profit margin declined to 28.7% from 30.8%. The company's trailing twelve months showed net sales of $23,885,000 with a gross profit margin of 24.3%, and a net loss of $4,657,000 ($0.66 per share).
Cyanotech (CYAN) reported Q2 fiscal 2025 financial results with net sales of $5.85M, down 8.3% from $6.37M in Q2 fiscal 2024. The company saw a 39% increase in bulk sales and 156% growth in contract extraction, while packaged goods decreased by 21%. Gross profit margin declined to 25.3% from 32.8%. The quarter resulted in a net loss of $1.15M ($0.16 per share) compared to $797K ($0.13 per share) last year. For the first six months, net sales increased 1.9% to $11.74M, though gross profit margin decreased to 25.2% from 31.4%, with a net loss of $2.35M.
Cyanotech (OTCQB: CYAN) reported financial results for Q1 FY2025, ended June 30, 2024. Net sales increased 15% to $5,898,000, primarily due to higher Astaxanthin sales. However, gross profit declined to $1,476,000 (25.0% margin) from $1,532,000 (29.8% margin) in Q1 FY2024. The company reported an operating loss of $1,041,000 and a net loss of $1,202,000 ($0.17 per diluted share).
CEO Matthew K. Custer highlighted the launch of Hawaiian Spirulina® gummies in May and noted that lower production levels over the past six quarters resulted in higher costs. The company is now focusing on increasing supply to meet changing demand and has preliminarily secured financing to support this effort.
Cyanotech announced its financial results for Q4 and FY 2024, ending March 31, 2024. The company reported annual net sales of $23.071M, a slight decrease of 0.5% from $23.178M in FY 2023. Gross profit for the year fell to $5.945M with a margin of 25.8%, down from $7.259M and 31.3% respectively. The operating loss widened to $4.592M from $2.920M, and the net loss increased to $5.267M or $0.81 per share, compared to $3.440M or $0.55 per share in FY 2023.
For Q4 FY 2024, net sales rose by 10.7% to $5.970M from $5.391M in Q4 FY 2023. However, gross profit dropped significantly to $675,000 with a margin of 11.3%, from $1.387M and 25.7% respectively. The operating loss was $1.903M, up from $1.255M, while net loss increased to $2.081M or $0.30 per share, from $1.430M or $0.23 per share.
CEO Matthew K. Custer highlighted shifts in product mix, increasing packaged sales but declining bulk spirulina sales due to price sensitivity. The company aims to meet rising demand with well-managed supply increases and has introduced new gummy formats for its flagship products.
Summary not available.
Summary not available.
Summary not available.